GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (STU:NTK1) » Definitions » Other Net Income (Loss)

NetScientific (STU:NTK1) Other Net Income (Loss) : €-0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is NetScientific Other Net Income (Loss)?

NetScientific's Other Net Income (Loss) for the six months ended in Jun. 2023 was €-0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.00 Mil.

NetScientific's quarterly Other Net Income (Loss) increased from Jun. 2022 (€-0.00 Mil) to Dec. 2022 (€0.00 Mil) but then declined from Dec. 2022 (€0.00 Mil) to Jun. 2023 (€-0.00 Mil).

NetScientific's annual Other Net Income (Loss) increased from Dec. 2020 (€-0.00 Mil) to Dec. 2021 (€0.00 Mil) but then declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.00 Mil).


NetScientific Other Net Income (Loss) Historical Data

The historical data trend for NetScientific's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific Other Net Income (Loss) Chart

NetScientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.01 -1.56 - - -

NetScientific Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NetScientific Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetScientific Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of NetScientific's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


NetScientific (STU:NTK1) Business Description

Traded in Other Exchanges
Address
20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG
NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (STU:NTK1) Headlines

No Headlines